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Introduction
Transurethral resection of the prostate (TURP) is the gold
standard against which all new operative treatments for be-
nign prostatic hyperplasia (BPH) are compared. However,
there are recognized risks associated with TURP such as the
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need for transfusion (2.5–4.2%),1,2 clot retention (5.5%)3 and
TUR syndrome (2–3%),1,2,4 and alternative surgical options
have been developed to reduce these.
Transurethral electrovaporation of the prostate is one
such option, and was first described by Kaplan and Te in
1995.5 Hammadeh et al demonstrated that it can achieve
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OBJECTIVE: Plasmakinetic vaporesection of the prostate (PKVP) using normal saline irrigation has the
theoretical advantage of avoiding transurethral resection syndrome and minimizing blood loss. It may also
shorten the operative time since tissue is resected instead of just vaporized. The aim of this study was to evaluate
the efficiency, safety and advantages of PKVP compared with standard transurethral resection of the prostate
(TURP) at a regional acute hospital.
METHODS: A total of 60 consecutive men admitted from a waiting list for surgery for benign prostatic
hyperplasia (BPH) were prospectively randomized to either PKVP or TURP. Peri- and postoperative outcome data
at 3 months were obtained.
RESULTS: The PKVP loop achieved a fast and sharp cutting action similar to that with the traditional TURP loop.
Data analysis was based on 51 patients. There were no significant differences between the methods in resection
time, postoperative catheterization time and hospital stay. The mean reductions in serum sodium 2 hours after
PKVP and on postoperative day 1 were 0.52 mmol/L and 3.35 mmol/L, respectively, while mean reductions in
haemoglobin were 0.36 g/dL and 0.24 g/dL, respectively. There was no significant difference in haemoglobin
reductions between PKVP and TURP (p = 0.326 at 2 hours; p = 0.192 on day 1) and serum sodium (p = 0.757 at 2
hours; p = 0.888 on day 1). Both groups achieved comparable improvement in International Prostate Symptom
Score (p = 0.862), quality-of-life score (p = 0.169) and peak flow rate (p = 0.96) at 3-month follow-up.
CONCLUSION: PKVP achieved comparable results to traditional TURP and was an effective and safe procedure.
However, it did not demonstrate obvious advantages over TURP in this acute regional hospital regular TURP list
setting. [Asian J Surg 2005;28(1):24–8]
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similar results to TURP in improving International Prostate
Symptom Score (IPSS), peak flow rate (Qmax) and reduction
in residual urine volume.6 A modification of this using a thick
loop, transurethral vaporization resection of the prostate
(TUVRP) is also safe and effective.7 However, these opera-
tions require monopolar diathermy in glycine and there is a
concern about glycine absorption.
Plasmakinetic vaporesection of the prostate (PKVP) is
claimed to be advantageous in terms of avoiding glycine since
it can be performed in a normal saline environment. It can also
achieve good haemostasis using the vaporization effect.8 The
development of the vaporesection loop may provide further
improvement by shortening the operative time and allowing
more precise resection, because the advantage of loop resec-
tion and the haemostatic effect of plasmakinetic vaporization
is combined. The aim of this study was to investigate the
efficiency and safety of transurethral PKVP and compare it
with conventional TURP.
Materials and methods
PKVP: mechanism of action
When current is passed through the active electrode of the
device, the active electrode approaches boiling point and a
plasma corona is formed, creating very high resistance be-
tween the active and return electrodes. Tissue entering the
plasma corona offers a lower resistance, so current arcs into
the tissue and circuits via saline to the return electrode. In this
study, tissue entering the corona was vaporized and adjacent
tissue was sealed to 0.5 mm (Figure 1).
Patients and methods
Between August 2001 and January 2002, a prospective ran-
domized controlled trial was conducted comparing PKVP
with standard TURP. Men admitted from the waiting list for
surgery for BPH were included in the study. The indications
for surgery were acute retention of urine and failure to remove
the catheter, chronic retention of urine due to prostatic ob-
struction causing renal impairment and severe lower urinary
tract symptoms (IPSS > 20 and Qmax < 10 mL/sec). Exclusion
criteria were known neurogenic bladder, known/suspected
prostate cancer, previous prostate surgery, urethral stricture,
bladder stone or warfarin therapy. All patients who took part
in the study had consented to participate.
Patients were randomized by computer-generated ran-
dom numbers. All operations were performed by a consultant,
senior medical officer or senior registrar experienced in per-
forming TURP. All patients and assessors were blinded to
treatment assignment.
A Wolf Fr27 continuous flow resectoscope with loop elec-
trode (Richard Wolf GmbH, Knittlingen, Germany) was used
for TURP, with the coagulation setting at 60 W and the cutting
current at 120 W generated from a Birtcher 6000 diathermy
machine (Conned Corp, USA). PKVP was performed using the
Gyrus plasmakinetic Fr27 resectoscope with a plasmakinetic
loop electrode (Gyrus Group PLC, Reading, UK). Plasmakinetic
energy was produced by a Gyrus generator (Gyrus Group PLC)
with the power setting at 240 W for vaporization and 60 W for
coagulation. Both operations were performed under spinal
anaesthesia and the surgical technique was similar.
At the end of the procedure, a 22 Fr three-way Foley
catheter was inserted and normal saline irrigation was contin-
ued for 4 hours. Irrigation was either stopped or continued
overnight according to the colour of the effluent compared
with a colour chart. If the effluent was lighter than the
predefined colour in the chart, irrigation was stopped. The
catheter was removed in the morning.
Haemoglobin and serum sodium levels were checked be-
fore and 2 hours and 1 day after surgery. Changes in haemo-
globin and haematocrit, serum sodium levels, catheterization
time and any complications were recorded. Clot retention was
defined as a clot requiring removal in the ward (catheter
change or washout) or in the recovery room of the operating
theatre. Urinary tract infection was defined as postoperative
fever with lower urinary tract symptoms, secondary haemor-
rhage or positive urine culture after surgery.
Student’s paired t test and the Chi-squared test were used
to compare continuous variables and categorical data,
respectively. Differences were considered significant at p less
than 0.05.
Figure 1. Mechanism of plasmakinetic vaporization.
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Results
Of the 60 patients enrolled in the study, 29 were randomized
to PKVP and 31 to TURP. A total of nine patients were ex-
cluded after randomization due to the following reasons:
eight for machine failure in the PKVP group, and one for
unfinished operation due to sepsis in the TURP group. The
analysis was based on 51 patients (21 PKVP and 30 TURP).
Patient characteristics are shown in Table 1.
There were no significant differences in resection time,
postoperative catheterization time and hospital stay (Table 2).
Two patients in the PKVP arm and six in the TURP arm needed
overnight irrigation, but this difference did not reach
significance. One patient in the TURP arm needed irrigation
for 2 days due to persistent haematuria. The mean weight of
the resected prostatic chip in the PKVP group was smaller than
that in the TURP group. The volume of irrigation fluid was the
same in both methods. Seven patients (4 in the PKVP arm and
3 in the TURP arm) developed retention of urine after Foley
catheter removal on postoperative day 1; in four of these
patients, it was possible to remove the Foley catheter 2 weeks
later, and the remaining three patients (2 PKVP and 1 TURP)
needed self-catheterization.
The mean reductions in serum sodium at 2 hours and on
postoperative day 1 in the PKVP group were 0.52 mmol/L and
3.35 mmol/L (Figure 2). The mean reductions in haemoglobin
at 2 hours and on postoperative day 1 in the PKVP group were
0.36 g/dL and 0.24 g/dL respectively (Figure 3). The reductions
were similar in both groups.
At 3-month follow-up, patients in both groups had achieved
comparable improvement in IPSS, quality-of-life score and
Qmax.
There were no major complications. The overall minor
complication rates were 23.8% in the PKVP group and 34.7% in
the TURP group. Four patients in each group developed uri-
nary tract infection. The PKVP group had a lower clot reten-
tion rate but this did not reach significance. No TUR syn-
drome was detected in either group.
Table 1. Patient characteristics
PKVP (n = 21) TURP (n = 30) p
Mean age (range), yr 72.5 (59–91) 1 73 (59–88) 0.781
Urinary retention, n (%) 17 (81) 1 1 25 (83) 8 1 0.951
Mean pre-op IPSS 15.82 (41– 100 19.36 81  81 81 0.457
Mean pre-op QoL 13.55 (14– 100 13.64 81  81 81 0.875
PKVP = plasmakinetic vaporesection of the prostate; TURP = transurethral resection of the prostate; pre-op = preoperative; IPSS =
International Prostate Symptom Score; QoL = quality-of-life score.
Table 2. Patient outcome
PKVP (n = 21) TURP (n = 30) p
Resection time (range), min 36.6 (12–76) 132.9 (12–105) 0.488
Resected weight (range), g 18.6 (1–57)1 25.1 (4–100) 0.147
Mean intraoperative irrigation volume (L) 11.6 (4– 100 12.2 (4–100) 0.722
Patients with successful 4-hour irrigation, n (%) 19 (90.5) 23 (76.7) 0.211
Post-op catheterization time (d) 1.14 (4– 100 1.21 (4–100) 0.594
Complications, n (%)
   Clot retention 1 (4.8) 15 (16.7) 0.211
   UTI 4 (19) 4 (19) 0.711
3 months’ post-op
   Mean change in IPSS 8.81 (4– 100 9.63 (4–100) 0.862
   Mean change in QoL 0.55 (4– 100 1.54 (4–100) 0.169
   Mean Qmax (mL/sec) 16.57 (4–ss 100 14.71 (4–  100) 0.961
PKVP = plasmakinetic vaporesection of the prostate; TURP = transurethral resection of the prostate; Post-op = postoperative; UTI = urinary
tract infection; IPSS = International Prostate Symptom Score; QoL = quality-of-life score; Qmax = peak flow rate.
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Discussion
PKVP theoretically offers the advantages of better haemostasis
and avoiding glycine. Better haemostasis allows surgery under
clear view and requires less time for coagulation of bleeding.
This should equate to a shorter resection time. The sharp
cutting action in PKVP using the PKVP loop is similar to that
in conventional TURP. However, PKVP uses a smaller loop
than conventional TURP and so requires more strokes per unit
volume of prostate resected, which offsets the resection time
saved (Figure 4). This may explain the lack of a difference in
resection time. The amount of irrigation fluid used in both
methods was comparable.
The systemic absorption of glycine contributes to TUR
syndrome. The risk of TUR syndrome increases from 0.7% to
2% if the resection time is longer than 90 minutes, and larger
prostates (> 45 g) are associated with a higher risk of TUR
syndrome (up to 1.5%).2,9 The risk of glycine absorption is
abolished using normal saline. Theoretically, PKVP allows
more time for resecting large prostates while reducing the risk
of TUR syndrome. In our study, the average resected weight
was only 22 g and resection time averaged around 30 minutes.
Thus, the proposed advantage of PKVP was not demonstrated.
Similarly, no additional benefit of PKVP was demonstrated in
reduced blood loss (as shown by no difference in haemoglobin
reductions) or clot retention.
It is interesting to note that other published series also
report similar mean weights of the resected gland.9,10 Thus,
the proposed advantage of PKVP for very large glands or
expected lengthy resection may not be relevant in routine
practice.
We acknowledge that the sample size in this study was
small. However, good results were achieved using TURP and
Figure 4. PKVP loop size versus TURP loop size. TURP = transurethral
resection of the prostate; TVP = transurethral electrovaporization of
the prostate; PKVP = plasmakinetic vaporesection of the prostate.
TURP loop TVP loop PKVP loop
the average resection weight in routine practice was small. One
may need a very large sample in order to demonstrate any
difference in outcome, and that kind of study may be difficult
in real life.
In conclusion, PKVP achieved comparable results to con-
ventional TURP and is a safe procedure. However, PKVP did
not demonstrate an obvious advantage over TURP in an acute
regional hospital regular TURP list setting.
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